Close Menu

NEW YORK – NantHealth said Friday after the close of the market that its fourth quarter revenues increased 6 percent year over year to $24.2 million.

In Q4 2019, NantHealth had total software-related revenues of $24.0 million, up 17 percent from $20.5 million in Q4 2018. Software as a service-related revenues grew to $18.4 million from $17.3 million, while software and hardware-related revenues nearly quadrupled to $2.9 million from $744,000. Maintenance revenues increased to $2.7 million from $2.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.